15.97
1.30 (8.86%)
| Previous Close | 14.67 |
| Open | 14.97 |
| Volume | 2,092,131 |
| Avg. Volume (3M) | 1,638,885 |
| Market Cap | 945,420,032 |
| Price / Sales | 3.52 |
| Price / Book | 1.37 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Profit Margin | -198.84% |
| Operating Margin (TTM) | -182.09% |
| Diluted EPS (TTM) | -8.91 |
| Quarterly Revenue Growth (YOY) | 27.30% |
| Total Debt/Equity (MRQ) | 67.12% |
| Current Ratio (MRQ) | 4.88 |
| Operating Cash Flow (TTM) | -281.85 M |
| Levered Free Cash Flow (TTM) | -185.65 M |
| Return on Assets (TTM) | -16.99% |
| Return on Equity (TTM) | -57.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ginkgo Bioworks Holdings, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.5 |
| Average | -0.38 |
|
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 6.88% |
| % Held by Institutions | 77.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Forbes J M & Co Llp | 30 Jun 2025 | 1,077,241 |
| 52 Weeks Range | ||
| Median | 9.00 (-43.64%) | |
| Total | 1 Sell | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 25 Aug 2025 | 9.00 (-43.64%) | Sell | 12.05 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Sep 2025 | Announcement | Ginkgo Datapoints and Apheris Launch Antibody Developability Consortium |
| 29 Aug 2025 | Announcement | Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions |
| 20 Aug 2025 | Announcement | Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry |
| 12 Aug 2025 | Announcement | Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth |
| 07 Aug 2025 | Announcement | Ginkgo Bioworks Reports Second Quarter 2025 Financial Results |
| 31 Jul 2025 | Announcement | Ginkgo Bioworks Announces Date of Second Quarter 2025 Results Presentation |
| 30 Jul 2025 | Announcement | Ginkgo to Deploy Modular Automation Technology to the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Labs (PNNL) to Accelerate Microbial Research for the Bioeconomy |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |